Alteogen Inc.
196170
Rang în acțiuni
#1844
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters,... ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology; and ALT-LS2, a SC (subcutaneous) formulation of trastuzuamb for the treatment of breast and gastric cancer. The company has a strategic alliance with Kissei Pharmaceutical for the development of ALT-L9, a biosimilar of Eylea (Aflibercept) which is currently under Phase 1 trial; Cristalia for the development of ALT-L2, a biosimilar of Herceptin (Trastuzumab), a monoclonal antibody for the treatment of breast cancer, which is in the Phase II clinical trial; and Biogen Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.
Preț acțiune
$165.61
Capitalizare de piață
$11.53B
Schimbare (1 zi)
4.13%
Schimbare (1 an)
-46.48%
Țară
KR
Tranzacționează Alteogen Inc. (196170)
Categorie
Healthcare
Raport P/S pentru Alteogen Inc. (196170)
Raport P/S la data de October 2026 TTM: 57.65
Conform celor mai recente rapoarte financiare și prețului acțiunilor Alteogen Inc., raportul P/S actual (TTM) este 57.65. La sfârșitul anului 2023, compania avea un P/S de 48.97.
Istoricul raportului P/S pentru Alteogen Inc. din 2012 până în 2026
Raport P/S la sfârșitul fiecărui an
| An | Raport P/S | Schimbă |
|---|---|---|
| 2026 (TTM) | 57.65 | -63.93% |
| 2024 | 159.83 | 226.37% |
| 2023 | 48.97 | -30.53% |
| 2022 | 70.50 | -28.71% |
| 2021 | 98.89 | -16.64% |
| 2020 | 118.63 | 287.21% |
| 2019 | 30.64 | 7.56% |
| 2018 | 28.48 | 18.57% |
| 2017 | 24.02 | -15.48% |
| 2016 | 28.42 | -42.35% |
| 2015 | 49.30 | 215.78% |
| 2014 | 15.61 | 51.19% |
| 2013 | 10.33 | -17.58% |
| 2012 | 12.53 | 0.00% |
Raport P/S pentru companii similare sau competitoare
| Companie | Raport P/S | Diferență raport P/S | Țara |
|---|---|---|---|
| 10.02 | -82.61% |
US
|
|
| 40.55 | -29.66% |
US
|
|
| 3.96 | -93.13% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | -82.40% |
NL
|
